Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 101 to 125 of 332

Guidance and quality standards awaiting development
Title	Type
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]	Technology appraisal guidance
Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]	Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]	Technology appraisal guidance
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]	Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]	Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]	Technology appraisal guidance
Elamipretide for treating Barth syndrome in people of any age [ID6545]	Technology appraisal guidance
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]	Technology appraisal guidance
Elinzanetant for Vasomotor symptoms [ID6544]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]	Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]	Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]	Technology appraisal guidance
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]	Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]	Technology appraisal guidance
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]	Technology appraisal guidance

Results per page

10
25
50
All